Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragmatic Hernia
Study Summary
This trial is testing if a new fetal therapy can help babies with a severe birth defect called Congenital Diaphragmatic Hernia (CDH) survive.
- Congenital Diaphragmatic Hernia
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: First 28 days of postnatal life
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Fetoscopic Endoluminal Tracheal Occlusion (FETO)
1 of 1
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: Fetoscopic Endoluminal Tracheal Occlusion (FETO) · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · Female Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many participants have joined this experiment thus far?
"Correct. Evident from clinicaltrials.gov, this medical trial is actively looking for individuals to participate. The first posting was on September 1st 2015 and the most recent update was on February 18th 2020. 15 people are required at one site location for this study." - Anonymous Online Contributor
Are there any remaining slots available for participants in this experiment?
"Per the information posted to clinicaltrials.gov, this trial is actively enrolling participants and has been since September 1st 2015 with a most recent update on February 18th 2020." - Anonymous Online Contributor